Additional protective or risk factors may be required in these patients to influence the clinical outcome of COVID-19, such as age or the nature of the AAN-I-IFNs (neutralizing IFNω and/or the 12 IFNα subtypes). This evidence concerns the gene IFNA2 and COVID-19.